BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in a Phase I/II clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra™ alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors.

Arcutis Biotherapeutics, Inc. today announced positive topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, in adults and children six years and older with mild to moderate atopic dermatitis (AD).

Daré Bioscience, Inc. today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related to development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.

PaxMedica, Inc. today provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022.

Nemaura Medical, Inc. today releases its financial results for the quarter ending September 30, 2022 and provides a business update.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”) today announced that researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

QSAM Biosciences Inc. today announces financial results for the third quarter ended September 30, 2022.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Today, Vyant Bio announces results for the third quarter of 2022.

Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd is pleased to advise that CEO and Managing Director, Dr David Foster will present at the World Antiviral Congress 2022 in San Diego, USA which runs from 28 November – 1 December 2022.

Rockfield Medical Devices Limited, a commercial-stage medical device company focused on developing solutions to transform the mobility and quality of life of tube feeders, today announced U.S. Food and Drug Administration (“FDA”) 510(k) clearance of the Mobility+ Enteral Feeding System.